TAS-102单药治疗及与贝伐单抗联合治疗转移性结直肠癌

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer.

作者信息

Liu Cheng-Jiang, Hu Ting, Shao Ping, Chu Wu-Yang, Cao Yu, Zhang Feng

机构信息

Department of General Medicine, Affiliated Anqing First People's Hospital of Anhui Medical University, 246000, China.

Department of General Practice, Anqing Municipal Hospital of Anhui Medical University, 246000, China.

出版信息

Gastroenterol Res Pract. 2021 Dec 20;2021:4014601. doi: 10.1155/2021/4014601. eCollection 2021.

OBJECTIVE

To evaluate the effectiveness and safety of TAS-102 monotherapy and combination therapy with bevacizumab in the treatment of metastatic colorectal cancer.

METHODS

The PubMed, Web of Science, MEDLINE, and Cochrane Library databases were searched for the literature on TAS-102 treatment of metastatic colorectal cancer. Extracted data include median overall survival (mOS), median progression-free survival (mPFS), and the incidence of adverse events for meta-analysis.

RESULTS

Our study found that the mOS of patients treated with TAS-102 monotherapy was 6.95 (95% CI: 6.26-7.72) months and the mPFS was 2.53 (95% CI: 2.31-2.78) months. The mOS in patients treated by TAS-102 combined with bevacizumab was 10.41 (95% CI: 8.40-12.89) months, and the mPFS is 4.35 (95% CI: 3.05-6.20) months. In the control experiment, the patients' mOS and mPFS were improved. TAS-102+B vs. TAS-102 (OR = 0.41, 95% CI: 0.18-0.93; OR = 0.72, 95% CI: 0.63-0.83) and TAS-102 vs. placebo (OR = 0.44, 95% CI: 0.29-0.67; OR = 0.51, 95% CI: 0.42-0.62) were studied to actively prevent the occurrence of neutropenia, leukopenia, febrile neutropenia, anemia, and vomiting.

CONCLUSION

TAS-102 monotherapy and combination therapy with bevacizumab can significantly improve the survival of patients and prevent specific adverse events from happening.

目的

评估TAS-102单药治疗及联合贝伐单抗治疗转移性结直肠癌的有效性和安全性。

方法

检索PubMed、Web of Science、MEDLINE和Cochrane图书馆数据库中有关TAS-102治疗转移性结直肠癌的文献。提取的数据包括总生存期中位数（mOS）、无进展生存期中位数（mPFS）以及不良事件发生率，用于荟萃分析。

结果

我们的研究发现，接受TAS-102单药治疗的患者mOS为6.95（95%CI：6.26 - 7.72）个月，mPFS为2.53（95%CI：2.31 - 2.78）个月。接受TAS-102联合贝伐单抗治疗的患者mOS为10.41（95%CI：8.40 - 12.89）个月，mPFS为4.35（95%CI：3.05 - 6.20）个月。在对照实验中，患者的mOS和mPFS均得到改善。研究了TAS-102 + B与TAS-102（OR = 0.41，95%CI：0.18 - 0.93；OR = 0.72，95%CI：0.63 - 0.83）以及TAS-102与安慰剂（OR = 0.44，95%CI：0.29 - 0.67；OR = 0.51，95%CI：0.42 - 0.62），以积极预防中性粒细胞减少、白细胞减少、发热性中性粒细胞减少、贫血和呕吐的发生。